PTHL
Pheton Holdings Ltd Class A Ordinary SharesNASDAQHealthcareAs of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.98
P/S
9.50
EV/EBITDA
-0.52
DCF Value
$0.47
FCF Yield
-97.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
82.9%
Operating Margin
-831.1%
Net Margin
-790.6%
ROE
-44.2%
ROA
-47.2%
ROIC
-52.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $67.5K | $-2.0M | $-0.14 |
| Q4 2024 | $237.7K | $-375.5K | $-0.03 |
| FY 2024 | $448.2K | $-661.0K | $-0.05 |
| Q2 2024 | $210.5K | $-285.1K | $-0.02 |
Company Info
Sector
Healthcare
Industry
—
Country
CN
Exchange
NASDAQ
Beta
5.33
Pheton Holdings Ltd, a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. The company's proprietary treatment planning system is a radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system is FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients. The company was founded in 1998 and is based in Beijing, China. Pheton Holdings Ltd operates as a subsidiary of ZJW (BVI) LTD.